GcMAF stands for Gc protein-derived macrophage. It is produced by modifying the Vitamin-D3 binding protein

It has been theorized that some cancer cell types have lost (or at least have it at a reduced amount) its macrophage-activating factor (MAF) due to a problem in the Gc protein (which is a precursor to MAF). These scientists suggest that cancer cells can produce a substance called Nagalase that is able to inhibit the Gc protein and, consequentially, the MAF.

GcMAF has been studied in various cancer types, for example, prostate, colon, lung, and breast, amongst others.

We don’t recommend the use of GcMAF under any circumstance. There are no sound data that can confirm its efficacy as an anti-neoplastic treatment neither as stand-alone nor as part of a more comprehensive treatment plan and our experience with the treatment is similar and hasn’t shown promise.